Search

Compugen Ltd

Uždarymo kaina

2.36 1.29

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.29

Max

2.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

663K

-7M

Pardavimai

426K

2.6M

P/E

Sektoriaus vid.

6.408

55.725

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-269.254

Darbuotojai

75

EBITDA

665K

-7M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+100.8% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.5M

231M

Ankstesnė atidarymo kaina

1.07

Ankstesnė uždarymo kaina

2.36

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-23 23:56; UTC

In after-market trading, Interactive Brokers Group Inc is roughly flat, with price fluctuations reflecting minimal movement since Wednesday's close.

2026-09-23 23:56; UTC

Correlated Moves

Allegiant Travel Co is trading modestly higher in after-market hours, recovering from earlier losses and currently positioned in the middle of its one-month trading range.

2026-09-23 23:56; UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026-09-23 23:56; UTC

Dow Inc saw a slight decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month range.

2026-09-23 23:55; UTC

Rush Street Interactive Inc. is trading roughly flat during after-market hours, following eight consecutive sessions with lower closes and remaining below its 20-day moving average.

2026-09-23 23:55; UTC

Endava PLC is seeing a slight decline in after-market trading, continuing a trend of lower daily closes and trading below its 20-day moving average.

2026-09-23 23:55; UTC

Delek US Holdings Inc is trading modestly higher during after-market hours, recovering from earlier declines while remaining below its 20-day moving average.

2026-09-23 23:55; UTC

Macro News

The U.S. Dollar Index is trading roughly flat, with macroeconomic developments highlighting oil supply from the Strait of Hormuz amid rising U.S. crude inventories.

2026-09-23 23:55; UTC

Cardinal Health Inc is trading modestly higher in after-market hours following slight fluctuations during the session, remaining below its 20-day moving average.

2026-09-23 23:52; UTC

Northrop Grumman Corp is declining in after-market trading, settling lower after briefly turning positive and remaining below its 20-day moving average.

2026-09-23 23:52; UTC

South Africa's Balance of Trade Data Release on September 30: Market Eyes Sustained Surplus Amid Mixed Economic Signals.

2026-09-23 23:52; UTC

Germany's Inflation Rate Expected to Remain Stable Ahead of September 30 Release Amid Geopolitical Tensions and Strong Manufacturing Activity

2026-09-23 23:52; UTC

Germany's Inflation Rate Release on September 30 Expected to Show Stability Amid Strong Manufacturing Growth and Geopolitical Tensions.

2026-09-23 23:52; UTC

Mixed Sentiment Ahead of U.S. New Home Sales Data Release Amidst Slowing Activity and Luxury Market Resilience

2026-09-23 23:52; UTC

New Home Sales Expected at 0.62 Million Amid Rising Prices and Cautious Market Sentiment

2026-09-23 23:52; UTC

Japan's Tankan Large Manufacturers Index set for release on September 30, amid mixed market sentiments influenced by global economic factors and rising interest rate concerns.

2026-09-23 23:51; UTC

Cleveland-Cliffs Inc has traded lower in after-market hours, pulling back from earlier highs while remaining above its 20-day moving average.

2026-09-23 23:51; UTC

Urban Outfitters Inc. is declining in after-market trading, falling significantly below its 20-day moving average and nearing the lower end of its one-month range.

2026-09-23 23:51; UTC

Guidewire Software Inc's shares are trading modestly higher in after-market hours, continuing a trend of gradual increases since Wednesday's close.

2026-09-23 23:51; UTC

Conagra Brands Inc is seeing modest declines in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026-09-23 23:51; UTC

Frontdoor Inc's shares advanced modestly in after-market trading, achieving nearly a 1% cumulative return since Wednesday's close, despite trading near the lower end of its range.

2026-09-23 23:51; UTC

Nu Holdings Ltd. saw a modest increase in after-market trading, recovering from a low point and marking a cumulative return of nearly 1%.

2026-09-23 23:51; UTC

West Pharmaceutical Services Inc is seeing a modest decline in after-market trading, positioned at the lower end of today's range but above its 20-day moving average.

2026-09-23 23:51; UTC

Cable One Inc is trading modestly higher in after-market hours, following a notable peak shortly after the regular session ended.

2026-09-23 23:51; UTC

Vertex Pharmaceuticals Inc saw a modest rise in after-market trading, recovering from a low return shortly after the market closed.

2026-09-23 23:46; UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

2026-09-23 23:46; UTC

Boyd Gaming Corp declined in after-market trading, moving from a slight gain to a loss, and is significantly below its 20-day moving average.

2026-09-23 23:46; UTC

Repligen Corp's stock declined in after-market trading, hitting its lowest point of the day after Wednesday's close, despite remaining above its 20-day moving average.

2026-09-23 23:46; UTC

CEVA Inc is trading modestly higher in after-market hours, maintaining strength above its 20-day moving average amid positive private sector activity indicators.

2026-09-23 23:46; UTC

Sirius XM Holdings Inc is down in after-market trading, marking four consecutive sessions of declines and remaining below its 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

100.8% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  100.8%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.